ArticleJournal for immunotherapy of cancer2016
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.
Article in Journal for immunotherapy of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis.Radiology · 2020Pooled it
- Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Guideline
- Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.Journal for immunotherapy of cancer · 2018Guideline
- Immunotherapy rechallenge after progression in non-small cell lung cancer: A systematic review and network meta-analysis.iScience · 2026Article
- Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study.Frontiers in immunology · 2025Article
- Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon.Frontiers in immunology · 2023Article
- Does CCL19 act as a double-edged sword in cancer development?Clinical and experimental immunology · 2022Review
- Article
- Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature.Frontiers in immunology · 2021Review
- Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.Journal of cancer research and clinical oncology · 2020Article
- Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.Current oncology reports · 2020Review
- Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Review
- iRECIST: how to do it.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.Cancer biology & medicine · 2019Article
- Review
- The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.International journal of molecular sciences · 2019Review
- A network approach to developing immuno-oncology combinations in Canada.Current oncology (Toronto, Ont.) · 2019Article
- Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.Medical oncology (Northwood, London, England) · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in comparison with RECIST1.1, which constitutes an important step to further understand immune-related response phenomena. This commentary discusses the key observations in the study in terms of their implications and pitfalls, and describes unmet needs that remain to be addressed. The article also emphasizes the important role of tumor response criteria as a "common language" to describe the results of cancer treatment, and discusses future directions for further advances of the field of immuno-oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.